| Pharmaceutical Formulations | Branded generics across therapeutic areas including cardiac, diabetic care, antibiotics, and pain management formulations. | Strong group distribution network, established brand recognition, and regulatory registrations across export markets. | B2B pharmaceutical distributors, hospitals, and B2C end customers through pharmacies in India and abroad. | Specialty branded generics in diabetic and cardiac care segments. | 121 | 40 | Revenue generated through direct sales to distributors, retailers, and healthcare institutions in domestic and export markets. | Primarily direct sales with negotiated pricing; product branding supports premium pricing in select segments. | Expanded product portfolio, increased market penetration, and rising demand in therapeutic segments like diabetes and cardiac care. | SITABEND, SITABEND-M, AZIWIN, CAFIMOL, Meloxi |
| Bulk Drugs and Active Pharmaceutical Ingredients (API) | Manufacturing of APIs for internal consumption and external supply catering to various pharmaceutical companies domestically and internationally. | In-house manufacturing capability with recently commissioned large-scale API production units and strategic acquisitions. | Pharma manufacturers and exporters; B2B focus domestically and internationally. | Specialty APIs like Gliclazide and Ebastine with increasing market demand. | 182 | 60 | Sales of bulk drugs to pharmaceutical manufacturers, export contracts, and captive consumption for formulations. | Contract-based sales and long-term supply agreements with volume discounts. | Establishment of integrated API units and acquisition of manufacturing units; increasing global demand for quality Indian APIs. | Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregabalin |
